Literature DB >> 18602958

The cost of preventing rabies at any cost: post-exposure prophylaxis for occult bat contact.

Caroline Huot1, Gaston De Serres, Bernard Duval, Renée Maranda-Aubut, Manale Ouakki, Danuta M Skowronski.   

Abstract

Investigations conducted by public health in Quebec, Canada, following report of human exposure to a bat were reviewed to evaluate the implementation of the recommendation for rabies post-exposure prophylaxis (RPEP) for household bat exposure (without documented direct contact). Of all RPEP recommended, 12% was for direct bat contact with bite, 7% for direct bat contact without known bite and 81% for household exposure. When bat was not available for testing, RPEP was almost always recommended. Household bat exposure has become the most frequent reason for RPEP administration. Given the rarity of rabies, RPEP recommendations related to household bat exposure may warrant review.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18602958     DOI: 10.1016/j.vaccine.2008.06.076

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Update on rabies diagnosis and treatment.

Authors:  Alan C Jackson
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

2.  Bat rabies and human postexposure prophylaxis, New York, USA.

Authors:  Millicent Eidson; Yoichiro Hagiwara; Robert J Rudd; Louise-Anne McNutt
Journal:  Emerg Infect Dis       Date:  2011-12       Impact factor: 6.883

Review 3.  A review of the circumstances and health-seeking behaviours associated with bat exposures in high-income countries.

Authors:  Eryn Wright; Satyamurthy Anuradha; Russell Richards; Simon Reid
Journal:  Zoonoses Public Health       Date:  2022-06-13       Impact factor: 2.954

Review 4.  A Systematic Review of Human Bat Rabies Virus Variant Cases: Evaluating Unprotected Physical Contact with Claws and Teeth in Support of Accurate Risk Assessments.

Authors:  Virginia M Dato; Enzo R Campagnolo; Jonah Long; Charles E Rupprecht
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.